720 results on '"Alexis, Andrew"'
Search Results
102. The Personalised Acne Treatment Tool (PATT) – Recommendations to facilitate a patient-centered approach to acne management from the Personalising Acne: Consensus of Experts (PACE)
103. Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis
104. Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials
105. Acne symptoms and impact of acne on social functioning, emotional functioning, and activities of daily living (ADL) among pediatric patients with moderate to severe non-nodular Acne Vulgaris (AV) in community practices across the U.S: PROSES study
106. Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S: PROSES study analysis by gender and age
107. Investigator global assessment (IGA) of Acne Vulgaris and IGA Success among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in community practices across the U.S in PROSES study: Analysis by concomitant medication
108. TREATMENT RECOMMENDATIONS FOR ACNE-ASSOCIATED HYPERPIGMENTATION: RESULTS OF A DELPHI CONSENSUS PROCESS AND LITERATURE REVIEW
109. Post-inflammatory Pigment Alteration
110. Etanercept
111. Pathways to diagnosis of non-small cell lung cancer: a descriptive cohort study
112. Tri-modality therapy in advanced esophageal carcinoma: long-term results and insights from a developing world, institutional cohort
113. Efficacy and Safety of Calcipotriene/Betamethasone Dipropionate Foam in the Treatment of Psoriasis in Skin of Color
114. Racial disparities in dermatology
115. Unmet needs for patients with seborrheic dermatitis
116. Risk-Adapted Target Delineation for Breast Cancer: Controversies and Considerations
117. Diversity, equity, and inclusion: The visionary future of JAAD
118. Tri-modality therapy in advanced esophageal carcinoma: long-term results and insights from a developing world, institutional cohort
119. Treating Acne in Adult Women
120. Advances in Acne and Rosacea Therapy
121. Skin Bleaching and Dermatologic Health of African and Afro-Caribbean Populations in the US: New Directions for Methodologically Rigorous, Multidisciplinary, and Culturally Sensitive Research
122. Using Distributed Agents for Patient Scheduling
123. Software Agents in Clinical Workflow, Clinical Guidelines and Clinical Trial Medicine
124. An Expert Panel Questionnaire for Assessing Patient-Reported and Caregiver-Reported Outcomes in Acne Vulgaris
125. Impact of acne on social functioning, emotional functioning, and activities of daily living among patients with moderate to severe non-nodular acne vulgaris administered sarecycline in real-world community practices across the U.S. (PROSES Study)
126. Patient Reported Outcomes (PROs) and Investigator Global assessment (IGA) of Acne Vulgaris among patients with moderate to severe non-nodular Acne Vulgaris (AV) administered sarecycline in real-world community practices across the U.S. (PROSES Study)
127. Efficacy and safety of up to two years of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis
128. Efficacy and safety of tralokinumab treatment in adults of different racial subgroups with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials
129. Carbene–Calcium Silylamides and Amidoboranes
130. Evolving Concepts in Psoriasis: Special Considerations for Patients With Skin of Color, Skin Barrier Dysfunction, and the Role of Adjunctive Skin Care
131. Health-Related QOL Differs by Race/Ethnicity in North American Patients with Psoriasis: Results from PSOLAR
132. 32496 Efficacy and safety of abrocitinib according to geographies
133. Software Agents in Clinical Workflow, Clinical Guidelines and Clinical Trial Medicine.
134. Using Distributed Agents for Patient Scheduling.
135. Patient-reported outcomes with sarecycline treatment for acne vulgaris: Pooled analysis of phase 3 clinical studies
136. 51907 VISIBLE: Guselkumab Provides Significant Improvements in Health-related Quality of Life in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis
137. 52871 Tapinarof Cream 1% Once Daily is Efficacious for the Treatment of Moderate to Severe Atopic Dermatitis in Patients with Skin of Color Down to 2 Years of Age in Two Pivotal Phase 3 Trials
138. 52714 Racial/Ethnic Differences Among Atopic Dermatitis Patients Regarding the Perceived Impact of Disease, Satisfaction With Treatment, and Communication With Care Team
139. 54671 Prevalence of melasma, impact on quality of life and social stigmatization: results of the first large international survey
140. 54772 Pigmentary disorders, prevalence, impact on quality of life and social stigmatization: Results of the first large international survey
141. 51125 PATIENT EXIT INTERVIEWS ILLUSTRATE BENEFIT OF TRIFAROTENE ON ACNE-INDUCED PIGMENTARY PROBLEMS
142. 52946 Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Black Participants with Moderate-to-Severe Acne
143. 50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis
144. 53113 Trifarotene shown to improve acne and related sequelae (scars, pigmentation)
145. 54728 Prevalence of post-inflammatory hyperpigmentation, impact on quality of life and social stigmatization: results of the first large international survey
146. 53447 Phase IV studies show trifarotene is efficacious and suitable for broad range of patient types
147. 53767 A practical algorithm for the integration of skincare to improve patient outcomes and satisfaction with energy-based dermatologic procedures
148. Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases
149. Etanercept in dermatology and off-label use
150. Melasma hyperpigmentation: An overview of current topical therapeutics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.